{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:41:18Z","timestamp":1793500878393,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13311-023-01440-x","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:01:56Z","timestamp":1697122916000},"page":"1682-1691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-436X","authenticated-orcid":false,"given":"Diane","family":"Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Belfiore-Oshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashmin","family":"Karten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessi","family":"Keavney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Kevin","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terina","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Montminy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn L.T.M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Sivakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1007\/s13311-023-01440-x_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaneurol.2022.1783","article-title":"Six action steps to address global disparities in Parkinson disease: a World Health Organization priority","volume":"79","author":"Schiess","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s43441-021-00275-y","article-title":"Value of data sharing to advance drug development: a regulatory perspective","volume":"55","author":"Thompson","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"6","key":"10.1007\/s13311-023-01440-x_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cts.12488","article-title":"The role of public\u2013private partnerships in catalyzing the critical path","volume":"10","author":"Maxfield","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1007\/s13311-023-01440-x_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nm0312-341","article-title":"Public-private partnerships need honest brokering","volume":"18","author":"Goldman","year":"2012","journal-title":"Nat Med"},{"key":"10.1007\/s13311-023-01440-x_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.878942","article-title":"Biomarkers in medicines development\u2014from discovery to regulatory qualification and beyond","author":"Hendrikse","year":"2022","journal-title":"Front Med."},{"issue":"1","key":"10.1007\/s13311-023-01440-x_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40900-018-0093-3","article-title":"Enhancing the incorporation of the patient's voice in drug development and evaluation","volume":"4","author":"Chalasani","year":"2018","journal-title":"Res Involv Engagem"},{"key":"10.1007\/s13311-023-01440-x_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fphar.2020.00043","article-title":"Views of European drug development stakeholders on treatment optimization and its potential for use in decision-making","volume":"11","author":"Saesen","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1007\/s13311-023-01440-x_bib8","article-title":"Real-world evidence \u2014 where are we now?","author":"Concato","year":"2023","journal-title":"NEJM [Internet]"},{"issue":"S2","key":"10.1007\/s13311-023-01440-x_bib9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/jcph.2143","article-title":"Model-informed approach supporting drug development and regulatory evaluation for rare diseases","volume":"62","author":"Li","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1007\/s13311-023-01440-x_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s43441-020-00255-8","article-title":"Effective data sharing as a conduit for advancing medical product development","volume":"55","author":"Karpen","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1007\/s13311-023-01440-x_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-023-00767-1","article-title":"Evidence from ClinicalTrials.gov on the growth of digital health technologies in neurology trials","volume":"6","author":"Masanneck","year":"2023","journal-title":"NPJ Digit Med."},{"issue":"Suppl 1","key":"10.1007\/s13311-023-01440-x_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000512500","article-title":"Precompetitive consensus building to facilitate the use of digital health technologies to support Parkinson disease drug development through regulatory science","volume":"4","author":"Stephenson","year":"2020","journal-title":"Digit Biomark"},{"key":"10.1007\/s13311-023-01440-x_bib13","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-202428","article-title":"Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective","author":"Stephenson","year":"2021","journal-title":"J Parkinsons Dis."},{"issue":"7","key":"10.1007\/s13311-023-01440-x_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington's disease: the integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib15","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cpt.2536","article-title":"Toward bridging unmet medical need in early Alzheimer's disease: an evaluation of beta-amyloid (A\u03b2) plaque burden as a potential drug development tool","volume":"111","author":"Zhu","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1007\/s13311-023-01440-x_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01440-x_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.712555","article-title":"Volumetric MRI-based biomarkers in Huntington's disease: an evidentiary review","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurol"},{"issue":"12","key":"10.1007\/s13311-023-01440-x_bib19","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jamaneurol.2022.3282","article-title":"Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review","volume":"79","author":"Shefner","year":"2022","journal-title":"JAMA Neurol"},{"issue":"19","key":"10.1007\/s13311-023-01440-x_bib20","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1089\/neu.2016.4729","article-title":"The traumatic brain injury endpoints development (TED) initiative: progress on a public-private regulatory collaboration to accelerate diagnosis and treatment of traumatic brain injury","volume":"34","author":"Manley","year":"2017","journal-title":"J Neurotrauma"},{"issue":"10","key":"10.1007\/s13311-023-01440-x_bib21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","article-title":"Serum neurofilament light as a biomarker in progressive multiple sclerosis","volume":"95","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/alz.12422","article-title":"Using the Alzheimer's disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease","volume":"18","author":"Veitch","year":"2022","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1007\/s13311-023-01440-x_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1073858421997035","article-title":"Alzheimer's dementia: the emerging role of positron emission tomography","volume":"28","author":"Tripathi","year":"2022","journal-title":"Neuroscientist"},{"issue":"5","key":"10.1007\/s13311-023-01440-x_bib24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer's disease","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat Med"},{"key":"10.1007\/s13311-023-01440-x_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.712565","article-title":"Recommendations to optimize the use of volumetric MRI in Huntington's disease clinical trials","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jalz.2013.07.003","article-title":"Coalition against major diseases\/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease","volume":"10","author":"Hill","year":"2014","journal-title":"Alzheimer's & Dementia"},{"key":"10.1007\/s13311-023-01440-x_bib27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fneur.2019.00482","article-title":"Magnetic resonance spectroscopy in ALS","volume":"10","author":"Kalra","year":"2019","journal-title":"Front Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01440-x_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort","volume":"79","author":"Willcocks","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01440-x_bib29","article-title":"Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials","author":"Kim","year":"2023","journal-title":"CPT: Pharmacomet Syst Pharmacol."},{"issue":"3","key":"10.1007\/s13311-023-01440-x_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.16","article-title":"The future is now: model-based clinical trial design for Alzheimer's disease","volume":"97","author":"Romero","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1007\/s13311-023-01440-x_bib31","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1001\/jama.2011.1837","article-title":"Accelerating identification and regulatory approval of investigational cancer drugs","volume":"306","author":"Esserman","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1007\/s13311-023-01440-x_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/17407745221110199","article-title":"Mobilizing the clinical trial ecosystem to drive adoption of master protocols","volume":"19","author":"Bronson","year":"2022","journal-title":"Clin Trials"},{"issue":"2","key":"10.1007\/s13311-023-01440-x_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JPD-191856","article-title":"Is it possible to conduct a multi-arm multi-stage platform trial in Parkinson's disease: lessons learned from other neurodegenerative disorders and cancer","volume":"10","author":"Zeissler","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-023-01440-x_bib34","unstructured":"Federal Register, Department of Health and Human Services,\u00a085 FR 25642. https:\/\/www.federalregister.gov\/d\/2020-07419"}],"updated-by":[{"DOI":"10.1007\/s13311-023-01453-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000}}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01440-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923020068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923020068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:37:49Z","timestamp":1710607069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923020068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1878747923020068"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01440-x","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s13311-023-01453-6","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01440-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01453-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}